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Abstract
Inflammatory macrophages are abundant in kidney disease, stimulating repair, or driving chronic inflammation and fibrosis.
Damage associated molecules (DAMPs), released from injured cells engage pattern recognition receptors (PRRs) on
macrophages, contributing to activation. Understanding mechanisms of macrophage activation during kidney injury may
lead to strategies to alleviate chronic disease. We identified Triggering-Receptor-in-Myeloid-cells (TREM)-1, a regulator of
TLR signaling, as highly upregulated in kidney inflammatory macrophages and tested the roles of these receptors in
macrophage activation and kidney disease. Kidney DAMPs activated macrophages in vitro, independently of TREM-1, but
partially dependent on TLR-2/24, MyD88. In two models of progressive interstitial kidney disease, TREM-1 blockade had no
impact on disease or macrophage activation in vivo, but TLR-2/24, or MyD88 deficiency was anti-inflammatory and anti-
fibrotic. When MyD88 was mutated only in the myeloid lineage, however, there was no bearing on macrophage activation
or disease progression. Instead, TLR-2/24 or MyD88 deficiency reduced activation of mesenchyme lineage cells resulting in
reduced inflammation and fibrosis, indicating that these pathways play dominant roles in activation of myofibroblasts but
not macrophages. To conclude, TREM-1, TLR2/4 and MyD88 signaling pathways are redundant in myeloid cell activation in
kidney injury, but the latter appear to regulate activation of mesenchymal cells.
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Introduction
Inflammatory monocytes which are recruited to sites of tissue
injury and differentiate into tissue effector macrophages have been
shown to play important roles in the progression of chronic kidney
diseases and the resolution of acute kidney injury [1,2]. We
previously showed that in mouse models of progressive kidney
injury, three subpopulations of macrophages can be discerned in
the kidney parenchyma defined by the cell surface marker Ly6C
[3]. The Ly6Chigh population was activated similarly to the M1
activation defined in vitro, and the Ly6Clow subpopulation bore
some similarities to M2a macrophages with the hallmarks of a
profibrotic population. We also showed that Ly6Chigh macro-
phages differentiate into Ly6Clow macrophages [3]. Overall
macrophages in this model promote injury and fibrosis. Since all
populations of macrophages were activated we hypothesized that
danger associated molecular patterns (DAMPs) may play impor-
tant roles in their activation and that specific pattern recognition
receptors (PRRs) may regulate the response of macrophages to
DAMPs.
Identification of injury molecules and receptors that activate
monocytes when they enter the injured kidney is critical to the
development of new treatments focused on macrophages.
Increasing evidence points to DAMPs, released from injured
parenchymal cells, as critical factors that contribute to the pro-
inflammatory phenotype in the injured kidney via PRR-binding
and subsequent activation of NF-kB, MAPK and inflammasome
signaling [4,5]. The PRRs that have been most intensely
investigated as receptors for DAMPs are the Toll-Like Receptors
(TLRs). TLRs are germline encoded transmembrane receptors
that recognize pathogen-associated molecular patterns and initiate
an intracellular signaling cascade leading ultimately to an
inflammatory response. All of the TLRs, with the exception of
TLR-3, require the MyD88 adapter protein for maximal response.
A number of DAMPs have been identified as ligands for different
TLRs, including mitochondrial DNA (TLR-9), histones (TLR-4),
hyaluronan fragments (TLR-2 and 4), high mobility group box -1
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(TLR-4), and several heat shock proteins (TLR-2 and 4) [6–12].
One hypothesis is that the array of DAMPs and associated bound
molecules to which monocytes are exposed, determines the state of
activation of the myeloid cells.
Triggering receptors expressed on myeloid cell (TREM) family
are a cell surface Immunoglobulin domain receptor family
restricted to myeloid lineage cells. The TREM family function
as modulators of cellular response, regulating positively and
negatively the activation of myeloid cells during inflammation.
The majority of TREM family members lack cytoplasm signaling
motif but associate with an ITAM containing signaling adaptor
protein, DAP12 which can recruit activating kinases including
Syk. TREM-1 was first characterized in infections, was highly
upregulated and has been implicated as an amplifier of
inflammation [13][14–17], functioning as an important co-
activator of the TLR [13,17,18] and NOD Like Receptor (NLR)
[19,20] signaling pathways. Several recent studies suggested that
TREM-1 may be an important and targetable effector molecule
not only in infections but also in sterile inflammation [21] in
pancreas [22,23], joints [24], gut [25,26] and eyes [4,27]. In
addition, TREM-1 is cleaved, and soluble TREM-1 is readily
detected in biological fluids of patients suffering from a variety of
diseases [28], suggesting a possible role as a decoy receptor that
competes for putative ligands and negatively regulates TREM-1
pathway activation.
In these studies we identified TREM-1 as a highly expressed
receptor in macrophages during sterile kidney injury. Further-
more, we investigated the role of TREM-1 and the related TLR
receptor signaling pathways in macrophage activation and disease
progression in the kidney.
Materials and Methods
Animals
CsfR1-iCre [29] (FVB) mice were bred with Myd88fl/fl mice
(C57BL/6) (Jackson Laboratories) and the F2 generation was used
for the experiments. Tlr22/2, Tlr42/2, Tlr2-42/2 and Myd882/2
(C57BL/6) mice were previously reported [30]. Dap122/2 mice
were previously reported [31,32]. All experiments were performed
under a protocol approved by the Department of Comparative
Medicine, University of Washington (Permit number 4244-01). All
surgery was performed under ketamine and xylazine anesthesia
and all efforts were made to minimize suffering.
Mouse Model of Kidney Injury with Fibrosis
Mice were anesthetized with ketamine/xylazine (100/10 mg/kg
i.p.) and Unilateral Ureteral Obstruction (UUO) or unilateral
Ischemia and Reperfusion Injury (U-IRI) were performed in adult
(8–12wk) mice as previously described [33]. In the U-IRI model,
left kidney was clamped for 40 minutes (females) at 36.8–37.3uC
core temperature. For the TREM-1 experiments, mice received
daily i.p. injections of 40 mg of purified TREM1-Fc or hIgG1, as
control, diluted in PBS, starting at the day of surgery until sacrifice
at day 5.
Tissue Preparation and Histology
Mouse tissues were prepared and stained as previously
described [33,34]. Primary antibodies against the following
proteins were used for immunolabeling: CD11b (e-bioscience
1:200), Ly6C (e-bioscience 1:200), anti-TREM-1 (R&D 1:200),
F4/80 (Invitrogen 1:200) and aSMA (Sigma 1:400). Slides were
incubated with Fluorescence (Cy3 or FITC)-conjugated secondary
antibodies (1:400–1:800, Jackson ImmunoResearch), mounted
with Vectashield/DAPI, and images were captured using a Nikon
TiE Inverted Widefield Fluorescence microscope at the Lynn and
Mike Garvey Cell Imaging Core at Institute for Stem Cell and
Regenerative Medicine of University of Washington. For mor-
phometric analysis of collagen fibril staining, deparaffinized
sections (3 mm) were stained with 0.1% picrosirius red [35,36].
Area of positive fluorescence/stain in 2006 magnification of 10
randomly selected images per mouse were quantified using Image
J software (http://rsbweb.nih.gov/ij/) [34,37].
Q-PCR
RNA was isolated from kidney tissue samples using TRIzol
(Invitrogen) according to standard protocol. First-strand cDNA
was synthesized using the iScript kit (Bio-rad). Real-time PCR was
performed using iTaq SYBR green supermix with ROX (Bio-rad)
and 7900HT ABI detection system (Applied Biosystems). Target
genes were normalized by Hypoxanthine phosphoribosyltransfer-
ase (HPRT) expression. The mRNA expression was calculated
using the 2-DDCt method and expressed as an n-fold difference
relative to the control group.
Kidney Danger Associated Molecular Pattern Preparation
Kidneys were collected from normal mice (control), or day 5
after UUO. Under sterile conditions kidney vasculature was
flushed with ice cold PBS. Under sterile conditions kidneys were
decapsulated, minced and incubated with 2ml of LIBERASE TL
(0.2mg/ml in DMEM/F12, Roche) and digested by shaking
vigorously in a water-bath (37uC, 30min). Five ml of PBS was
added, then the single cell preparation filtered through a 40 mm
Cell Strainer. The filtrate was centrifuged (2000rpm, 5min at 4uC)
to pellet any cellular debris and the cell-free supernatant was
filtered using 0.2 mm low protein binding syringe filter. Polymyxin
B beads (Sigma P1411), 20 ml, were added to the supernatant and
incubated at 4uC for 30 minutes to remove any contamination by
endotoxin. Supernatant containing DAMPs centrifuged (2000rpm,
5min, 4uC) to remove beads, and aliquots were stored at 280uC
until use.
Bone Marrow Macrophage and Pericyte Isolation
BMDMw were generated by flushing femurs with DMEM/F12
as previously described [29]. BMDMw was cultured for 7 days in
macrophage medium (DMEM/F12 medium (Cellgro), containing
10% FBS (Invitrogen), 1% Penicillin/Streptomycin (Cellgro), 20%
L929 conditioned media containing M-CSF and stimulated on day
8. Pericytes from normal kidney from C57BL/6 wild-type, Tlr2–
42/2 and Myd882/2 mice were isolated using MACS (Miltenyi
Biotech) and rabbit polyclonal anti-PDGFRb antibody as detailed
previously [37].
Bone Marrow Macrophage and Pericyte Stimulation
BMDMw were incubated in 24well/plate (0.56106 cells/well)
with 1ml of DMEM/F12 serum-free media per well, containing
100 ml of crude DAMPS from injured or normal kidney, or 100 ml
of Liberase mix as control. To activate TREM-1 in BMDMw,
anti-TREM-1 antibodies (R&D) at 1 or 2 mg/ml or isotype IgG
control (R&D) were applied. To block TREM-1 activity, purified
TREM1-Fc or human IgG (Sigma) was applied at 1 or 3 mg/ml.
Pericytes between passages 2 and 5 were stimulated in 12-well
plates pre-coated with gelatin when 60–80% confluent. The
concentrations of IL-6 and MCP-1 in the supernatants of primary
pericytes were determined using enzyme-linked immunosorbent
assay kits (BioLegend) according to the vendor’s protocols.
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TREM1-Fc Generation and Purification
Trem1 ORF was cloned from cDNA from LPS activated
BMDMws. To generate a soluble TREM1-Fc fusion protein, the
cDNA encoding the extracellular region of Trem1 (position 57 to
position 659 in the gene; NCBI Reference NM_021406.5) was
amplified by PCR, digested and subcloned, in frame, into the
multiple cloning site of (pFUSE-hIgG1-Fc1, InvivoGen) contain-
ing the Fc region of human IgG1 (hinge, CH2, CH3), and
confirmed by sequencing. Plasmid DNA was obtained by
Maxiprep (Qiagen) and transfected using lipofectamine LTX
reagent (Invitrogen) to approximately 60% confluent 293T cells in
75 flasks that were seeded the day before. After 24h of transfection,
cells were washed with PBS, and incubated with DMEM/F12
serum-free media for 4 days. Supernatant was collected, centri-
fuged, filtered and TREM1-Fc protein was purified by affinity to
Protein A - Sepharose beads column (Invitrogen) using standard
methods described [38]. After elution, TREM1-Fc was dialyzed
for 16h at 4uC, using 20.000 MWCO cassettes (Thermo Scientific)
to exchange the current elution buffer to PBS. Presence and purity
of TREM1-Fc protein was confirmed by SDS PAGE gel stained
with Gel Code Blue Safe Protein Stain (Thermo Scientific) and
western blot using anti-TREM-1 antibody (R&D).
SDS PAGE and Western Blotting
Kidneys or BMDMws lysates were separated on 10% SDS-
PAGE gel (Bio-rad) then semi-dry transferred to an Immobilon
PVDF membrane as described [37,39]. After blocking, mem-
branes were incubated overnight with primary antibodies, anti-
TREM-1 (R&D, 1:1000), anti-MyD88 (ProSci, 1:500), b-Actin
(Santa Cruz, 1:1000), anti-HMGB1 (BioLegend 1:1000), anti-
mouse IgG (Jackson ImmunoResearch, 1:2500). Horseradish
peroxidase-conjugated secondary antibodies (Pierce) were applied
and enhanced chemiluminescence (Thermo Scientific) was used to
detect proteins, and images collected by FluorChemQ machine
(Alpha Innotech Corporation).
Statistical Analysis
Statistical evaluation was carried out using the One Way
Analysis of Variance (ANOVA) followed by Tukey post-test using
GraphPad Prism (GraphPad Software). A p value ,0.05 was
considered to be significant. Error bars indicate standard error of
mean.
Results
TREMs are Highly Upregulated in Mouse Models of
Chronic Kidney Injury
We purified macrophage subpopulations, discriminated by the
subpopulation marker, Ly6C, from kidneys 5 days after inducing
progressive interstitial kidney disease by unilateral ureteral
obstruction (UUO) using flow sorting (see Methods S1).
Neutrophils and NK cells were excluded (Fig. S1). The
transcriptome of those macrophage subpopulations was interro-
gated by microarray to identify regulated genes that separate M1
(Ly6Chigh) from M2a (Ly6Clow) type macrophages in vivo. Using a
highly stringent algorithm to identify regulated genes (Fig. S2), we
discovered that the majority of genes were down regulated from
comparing Ly6C+ to Ly6Clow cells and that the genes could be
clustered in terms of biological processes, including immune
response, response to stimulus, migration and chemotaxis. Among
the immune response genes were many associated with either
pattern recognition or activation (Trem1, Trem3, Pglyrp1, Clec4d,
Clec4e, Tsg6 and Schlafen4, S100a8 and S100a9), strongly suggesting
that Ly6Clow macrophages down-regulate activation pathways
compared with Ly6C+ macrophages. Since TREM-1 has been
shown to be an important co-activator of macrophages in
inflammatory diseases, we investigated the function of TREM-1
further in sterile kidney injury. To validate the transcriptional
analysis we quantified transcripts for the TREM family by
quantitative RT-PCR (Q-PCR) of whole kidney or purified
macrophage subpopulations or autologous blood monocytes
during the evolution of the UUO model of progressive kidney
injury (Fig. 1A–B). Trem1 was highly upregulated in whole kidney,
5 and 10 days after UUO, as well as in a second model of kidney
injury with chronic inflammation and fibrosis, unilateral ischemia
and reperfusion injury (U-IRI) (Fig. 1A). In the UUO model,
Trem1 was particularly upregulated in Ly6Chigh and intermediate
macrophages purified from the kidney (Fig. 1B). Trem3 expression
mirrored the regulation pattern of Trem1 except that Trem3 was
highly expressed by blood monocytes (Fig. 1B). Trem2 was also
expressed by monocytes, upregulated in Ly6Chigh macrophages,
but unlike Trem1 and Trem3, was further upregulated in Ly6Clow
macrophages (Fig. 1B). Similarly to transcript levels, TREM-1
protein was not detected in normal kidney but highly upregulated
during the progression of the UUO model (Fig. 1D–E), and its
expression was restricted to CD11b+ and Ly6C+ cells (Fig. 1C).
TLR-2 and TLR-4 but not TREM-1, Regulate Activation of
Macrophages in vitro by Kidney DAMPs
To study the signaling pathways in DAMP-mediated activation
of macrophages in kidney injury and the role of TREM-1 and
TLRs in this activation, we separated extracellular soluble factors
from injured kidney (kidney DAMPs) or normal kidney (control)
and applied these factors to primary cultures of quiescent bone
marrow derived macrophages (BMDMws) as a model of macro-
phage activation in vitro. Kidney DAMPs specifically stimulated Il-
1b expression, an effect lasting 24h (Fig. 2A). Kidney DAMPs also
activated Trem1 expression highly at 8h, but this response returned
to baseline at 24h, a finding suggestive that TREM-1 may play a
role in enhancing DAMP responses in macrophages and consistent
with the findings that kidney macrophages are activated and
produce TREM-1 (Fig. 2B). Kidney DAMPs did not induce Tnf-a
production (not shown), similarly to our previous studies which
showed kidney macrophages did not show Tnf-a activation [3].
Pre-incubation of BMDMws with IFNc for 8h markedly
augmented subsequent kidney DAMP responses (Fig. S3A)
suggesting either that cells have been primed by IFNc to respond
more strongly to DAMPs, similar to the enhancement during TLR
agonist stimulation, or, alternatively that IFNc upregulates DAMP
receptors. To explore the nature of kidney DAMPs further, the
crude kidney DAMPs were separated by SDS PAGE and proteins
detected by Coomassie blue stain (Fig. S3B) (see Methods S1).
Although, multiple protein bands were visualized in the normal
kidney preparation (control), several bands appeared in the
DAMPs preparation only suggesting these might be candidate
protein DAMP molecules in the soluble preparation (Fig. S3B).
High-mobility group protein B1 (HMGB1), which has been
previously described to be a ligand for TREM-1 [40,41], was one
such DAMP molecule found in abundance in kidney DAMPs
(Fig. S3C). Boiling almost completely attenuated biological
activity of kidney DAMPs (Fig. S3D). When kidney DAMPs
were exposed to trypsin or pronase, however, there was no impact
on DAMPs activity, suggesting these DAMP factors specific to
macrophages are either resistant to degradation or are non-
proteinaceous (Fig. S3E).
We hypothesized that cell surface TREM-1 may function as a
co-activator of macrophages during activation by kidney DAMPs.
We cloned mouse Trem1, and generated an Fc-fusion protein with
TREM-1, TLR-2 and TLR-4 in Kidney Injury
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the Trem1 ectodomain and the human IgG1 Fc domain to use as a
decoy receptor to block TREM-1 activation (Fig. S4A), a method
used successfully by others, such as in attenuating macrophage
activation by LPS [13,17]. To validate our protein, we stimulated
BMDMws with LPS and treated with TREM1-Fc or anti-TREM-
1 antibodies, which triggers TREM-1 cell surface clustering and
activates TREM-1 signaling. TREM1-Fc abrogated macrophage
activation by LPS, and anti-TREM-1 amplified this activation
(Fig. S4B–C). We then investigated the role of TREM-1 in
BMDMw-activation by kidney DAMPs. In contrast to the results
observed with LPS, activation of surface TREM-1 by anti-TREM-
1 antibodies did not augment DAMP-mediated activation of
macrophages in vitro (Fig. 2C), and purified TREM1-Fc did not
significantly inhibit DAMP-mediated activation of macrophages
in vitro (Fig. 2D). Because TREM-1 is only expressed after
exposure to DAMPs, we also pre-activated macrophages with
kidney DAMPs, and subsequently blocked DAMP-mediated
activation with TREM1-Fc or activated with anti-TREM-1, but
this experiment also provided no evidence of inhibition or
amplification of activation (Fig. S4D). In addition, we pre-
incubated kidney DAMPs overnight with TREM1-Fc conjugated
beads. TREM-1 bound DAMPs were then separated by centri-
fugation and the remaining supernatant was applied to macro-
phages. Compared with controls, TREM1-Fc adsorption did not
attenuate DAMP activity (Fig. S4E). Furthermore, we tested
whether DAMPs could activate DAP12 by signaling through
membrane bound TREM-1. We stably expressed a fusion protein
of TREM-1 with DAP12 in NFAT-Lacz reporter cells (BWZ
TREM1/DAP12) (see Methods S1). Signaling via DAP12
activates the NFAT promoter driving b-galactosidase production,
which can be detected by a colorimetric assay. Using this cell line,
anti-TREM-1 antibodies in suspension or coated to a plate
robustly activated DAP12 signaling and production of b-galacto-
sidase (Fig. S4F–G). However, kidney DAMPs either coated to
Figure 1. TREMs are highly expressed in macrophages during kidney injury. (A) Q-PCR for Trem1 expression in whole kidney 0, 5 and 10
days after UUO and U-IRI. (B) Q-PCR for TREM family transcript expression in blood monocytes, and different sub-populations of kidney macrophages
purified at day 5 after UUO. (C) Fluorescence images showing CD11b (green), Ly6C (green) and TREM-1 (red) expression in tissue sections from
control kidney (sham), day 3 and 10 after UUO (a, arteriole; Bar = 25 mm; arrowhead shows interstitial CD11b+ and TREM-1+ cells; arrow shows
autofluorescent arteriole internal elastic lamina). (D) Western blot of whole kidney lysates detecting TREM-1 (23kD) and b-Actin (43kD), 0, 3, 7, 10 and
14 days after UUO. (E) TREM-1 protein densitometry normalized to endogenous control b-Actin. (n = 3–5/group, 3 independent experiments;
*P,0.05).
doi:10.1371/journal.pone.0068640.g001
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plates or in suspension did not activate LacZ, and therefore
DAP12, in these reporter cells, suggesting TREM-1 is not a major
target for endogenous activators of innate immune responses.
Finally, to test whether TREM-1 may have ligands on dying
epithelial cells, the binding capacity of TREM1-Fc to apoptotic
kidney proximal epithelial cells (LLC-PK1) was evaluated, but no
differences were seen compared to healthy epithelial cells (data not
shown) [42].
Because TREM-1 is a regulator of TLR signaling, we next
investigated whether TLR-2, TLR-4 and MyD88 signaling
pathways played any role in DAMP-mediated activation. Using
macrophages deficient in TLR-2, TLR-4, TLR-2 and 4 or
MyD88, we assessed their responsiveness to kidney DAMPs. Both
Toll like single receptor deficiency in macrophages attenuated the
production of Il-1b in response to DAMPs, but this inhibition was
not enhanced significantly in macrophages lacking both receptors,
suggesting they have overlapping specificities for DAMP activity
(Fig. 2E). MyD88 deficient macrophages were also hypo-
responsive to kidney DAMPs (Fig. 2E). The hypo-responsiveness
was most strikingly seen in terms of Trem1 transcript induction
(Fig. 2F). Collectively these findings suggest TREM-1 does not
play a role in macrophage activation in vitro by DAMPs, and TLR-
Figure 2. TLR-2 and TLR-4 but not TREM-1, regulate activation of macrophages in vitro by kidney DAMPs. (A–B) Q-PCR showing Il-1b
and Trem1 expression in BMDMw stimulated for 8, 16 or 24h with soluble factors prepared from normal kidney (control) or disease kidney (kidney
DAMPs). (C–D) Graphs showing Il-1b and Trem1 expression by Q–PCR, 16h after BMDMw were stimulated with kidney DAMPs and (C) activating anti-
TREM-1 antibodies, or (D) TREM1-Fc, which blocks TREM-1 receptor by competing for ligands. (E–F) Q-PCR showing (E) Il-1b and (F) Trem1 expression
in BMDMw isolated from WT, Tlr22/2, Tlr42/2, Tlr2–42/2, and Myd882/2 mice stimulated with kidney DAMPs for 16h. Q-PCR results were normalized
to their respective control group. (*P,0.05, n = 5–7/group, 3 independent experiments; ns, p is not significant).
doi:10.1371/journal.pone.0068640.g002
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2, TLR-4 and the MyD88 signaling pathway are activated by
kidney DAMPs, but that other signaling pathways are also
responsible for activation.
Circulating TREM1-Fc does not Prevent Macrophage
Activation, Injury and Fibrosis in Models of Kidney
Disease
Our studies indicated that TREM-1 did not play a functional
role in BMDMw activation in vitro. To test whether this translated
to in vivo kidney disease, we induced two different models of kidney
injury in mice, UUO and U-IRI, which are characterized by
progressive interstitial inflammation and fibrosis [35], and
administered TREM1-Fc daily by i.p. injections at a dose of
40 mg/mouse, to give a predicted ECF volume concentration of
4 mg/ml or control human IgG1 (Fig. 3A). On d2 of the
experiment, 2 ml of venous blood was assessed for the presence of
TREM1-Fc, which was abundant in mice receiving TREM1-Fc
injections but not in mice receiving hIgG injections (Fig. 3B). In
both models, whole kidney analysis of macrophage activation
genes indicated that TREM1-Fc had no clear impact on
macrophage activation (Fig. 3C, S5A). Because both of these
models result in a fibrogenic process, we also evaluated Col1a1 and
Acta2 transcripts, as indicators of myofibroblast activation and
fibrogenesis finding no differences (Fig. 3C, S5A). TREM1-Fc
administration had no impact on the extent of macrophage
recruitment to the kidney, as well as the extent of aSMA+
myofibroblasts and collagen deposition (Fig. 3D, S5B). Since
TREM-1 signals via the co-receptor DAP12 we evaluated the
effect of DAP12 deficiency on the extent of U-IRI kidney disease.
Consistent with our observations with administration of TREM1-
Fc in vivo, Dap122/2 mice had similar disease severity compared
with strain-matched controls (Table S1).
The TLR-2, TLR-4 and MyD88 Pathways Play a Role in
Inflammation and Fibrosis in the U-IRI Model of Sterile
Kidney Injury
The observations from in vitro studies (Fig. 2) suggested that
TLR-2, TLR-4 and MyD88 might be partially responsible for
macrophage activation in vivo. To explore this possibility further,
we studied the progression of two models of kidney disease in mice
deficient in TLR-2, TLR-4 and MyD88 (Fig. 4; S6). Mice lacking
MyD88 or both TLRs showed evidence of significant reduction in
pro-inflammatory cytokine production in the U-IRI model
(Fig. 4A,D), but the pattern of reduction was distinct, suggesting
that MyD88 deficiency may disrupt signaling from TLRs other
than TLR-2 and TLR-4 or disrupt signaling from MyD88-
dependent cytokine receptors such as the IL-1 or IL-18 receptors.
In both experiments, the Trem1 transcript level, which is an
indicator of macrophage activation, was similar to the wild type
group, suggesting that macrophage activation was not different.
More strikingly was the observation that both Col1a1 and Acta2
gene transcripts were reduced by approximately 50% in mice
following kidney U-IRI and this was similar between MyD88 and
TLR-2/TLR-4 deficiency (Fig. 4B,E). These gene transcripts are
restricted to the pericyte/fibroblast/myofibroblast lineage, sug-
gesting that deficiency of MyD88 and TLR-2/TLR-4 was
impacting mesenchyme cell activation in the U-IRI model
predominantly. Furthermore, the epithelial injury marker Kim-1
was elevated similarly in MyD88 or TLR-2/TLR-4 deficiency,
suggesting that epithelial injury was not different between the
mutant and wild type mice and that these activating receptors may
not be critical in epithelial cells (Fig. 4B,E). In addition, the extent
of aSMA+ myofibroblasts and the extent of macrophage
recruitment to the kidneys was reduced when MyD88 or TLR-
2/TLR-4 were deleted (Fig. 4C,F). Although deficiency of TLR-
2, TLR-4 and MyD88 all had anti-inflammatory and anti-fibrotic
effects in the U-IRI model, the UUO model was completely
insensitive to deletion of these genes, indicating that the factors
stimulating activation and injury in the UUO model did not
involve the TLR-2, TLR-4 or MyD88 pathways (Fig. S6).
The TLR-2/TLR-4/MyD88 Pathway is Dispensable in
Macrophage Activation in Kidney Fibrosis, but Important
in Mesenchymal Cell Activation
To test the importance of these activating receptors in myeloid
cells further, we generated mice lacking MyD88 somatically in
myeloid lineage cells (macrophages, dendritic cells and neutro-
phils) Csf1R-iCre; Myd88fl/fl [29]. To validate the deletion of
MyD88 in myeloid lineage cells, we generated BMDMws from
these mice and Csf1R-iCre; Myd88+/+ littermates. As expected the
WT mice expressed high levels of MyD88, which was further
induced by LPS (Fig. S7A), but Csf1R-iCre; Myd88fl/fl showed no
detectable MyD88 protein. Similarly, BMDMws from Csf1R-iCre;
Myd88fl/fl mice were completely insensitive to LPS (Fig. S7B), a
result phenocopied using BMDMws from mice with germline
MyD88 deficiency. These results indicate that MyD88 is
completely deleted in myeloid lineage cells in the Csf1R-iCre;
Myd88fl/fl mice. Unexpectedly, deletion of MyD88 only in myeloid
cells resulted in no difference in pro-inflammatory cytokines or
chemokines in the U-IRI kidney injury model (Fig. 5A). In
addition, whereas the MyD88 deficient mice showed protection
from myofibroblast activation (Fig. 4E), Csf1R-iCre; Myd88fl/fl
mice showed no evidence of a reduction in myofibroblast
activation (Fig. 5B) and the extent of aSMA+ myofibroblasts
(Fig. 5C). Although the Csf1R-iCre; Myd88fl/fl mice were an F2
generation of FVB crossed with C57bl/6 mouse strain, the extent
of disease observed in the Csf1R-iCre; Myd88+/+ was identical to
C57bl/6 wild type (Fig. 4), therefore these findings suggest that in
the U-IRI model, these pathways are dispensable for macrophage
activation.
Because TLR-2, TLR-4 and Myd88 germline deficiency had
marked affects on myofibroblast activation and fibrogenesis, we
hypothesized that these receptors may be important mesenchymal
cell (myofibroblast progenitor) activation. We therefore generated
primary cultures of kidney pericytes (myofibroblast progenitors)
and stimulated them with kidney DAMPs. Pericytes robustly
activated Il-6 and MCP-1 (Fig. 5D–E) but not Il-1b in response to
DAMPs (Data not shown). Our studies predicted that MyD88,
TLR-2 and TLR-4 may play a role in DAMP- mediated activation
in pericytes. To test these we cultured MyD88, and TLR-2/TLR-
4 deficient pericytes. Pericytes deficient in MyD88 or TLR-2/
TLR-4 were not activated when stimulated with kidney DAMPs
(Fig. 5D–E). Pericytes in culture express high-baseline levels of
Col1a1 transcript, and DAMPs did not further increase Col1a1
production. However, pericytes deficient in MyD88 and TLR-2/
TLR-4 expressed very low baseline levels of Col1a1 transcript
when compared to wild type pericytes, and stimulation with
kidney DAMPs did not induce Col1a1 (Fig. 5D), indicating that
TLR-2/TLR-4 and MyD88 pathways are important for mesen-
chyme cell activation.
Discussion
These studies show that although TREM-1 is highly upregu-
lated in two models of chronic kidney disease in mice, and can
regulate TLR sensitivity to LPS, it plays no role in sterile activation
of monocytes/macrophages that are recruited to the injured
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kidney. These studies also show that, although the TLR-2, TLR-4
and MyD88 signaling pathways may play a small role in activation
of macrophages by kidney DAMPs in vitro, they are largely
dispensable in vivo. However, MyD88-dependent TLR-2, TLR-4
signaling appears to be critical in activation of mesenchymal cells
of the kidney.
TREM genes were highly upregulated in the kidney in Ly6C+
macrophages in response to injury. Several studies report a similar
response in sterile inflammation in other organs, and report that
TREM-1 blockade either by TREM1-Fc or by a peptide,
attenuates the disease process [23–26]. Our studies in the kidney
do not support a functional role for TREM-1 despite the
similarities between the studies. This may reflect differences in
DAMPs released in different organs, or the differing roles of
macrophages in each tissue. The fact that the mouse TREM-3
gene lies adjacent to the TREM-1, and studies have shown that
both receptors have redundant functions in the mouse [43,44],
suggests that TREM-3 could be compensating for TREM-1 in our
model. However, like TREM-1, TREM-3 is reported to signal
through DAP12 to function as an amplifier of inflammation. Our
findings indicate that Dap122/2 mice (Table S1) and Trem-22/2
mice (not shown) had similar disease severity compared to strain-
matched controls, suggesting that these pathways are dispensable
in these models of kidney injury.
The studies presented here show a novel method for studying
kidney DAMPs. The preparation method although crude, robustly
and reliably activates leukocytes and can be used to dissect
individual DAMP factors. The fact that DAMPs are heat sensitive,
but not sensitive to trypsin and pronase, indicates that they may be
non-proteinaceous factors, including nucleic acids, lipids or
products of extracellular matrix. However, they also could be
protein complexes resistant to proteolytic digestion. Consistent
Figure 3. Treatment with soluble TREM1-Fc does not prevent macrophage activation, injury and fibrosis in sterile kidney injury. (A)
Schema showing experimental design. Mice were subjected to unilateral ischemia and reperfusion injury (U-IRI) and treated daily with 40 mg/mouse
of TREM1-Fc or hIgG, as control. (B) Western blot showing presence of TREM1-Fc (approximately 56kD) in 2 ml of plasma collected at day 2 from mice
treated daily with 40 mg of TREM1-Fc. Anti-mouse IgG was used as endogenous control. (C) Q-PCR for different inflammatory transcripts (left) or pro-
fibrotic transcripts, Collagen1a1 (Col1a1) and alpha smooth muscle actin (Acta2), from whole kidney day 5 after U-IRI. (D) Representative images (left)
and quantitative graphs (right) showing+F4/80 cells (green),+aSMA (red) or collagen deposition (Sirius Red staining) day 5 after U-IRI. (*P,0.05, n = 5–
7/group, 3 independent experiments; Bar marker = 50 mm; Q-PCR results were normalized to sham +hIgG).
doi:10.1371/journal.pone.0068640.g003
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Figure 4. The TLR-2/TLR-4/MyD88 pathways play a role in fibrosis in the U-IRI model of sterile kidney injury. (A–C) Tlr2–42/2 (D–F)
Myd882/2 mice or respective controls were subjected to U-IRI and kidney harvested for tissue analysis 5 days later. Q-PCR (A,D) for different
inflammatory transcripts, (B,E) pro-fibrotic transcripts, collagen1a1 (col1a1) and alpha smooth muscle actin (Acta2), and the tubule injury marker,
kidney injury molecule-1 (Kim-1) from whole kidney day 5 after U-IRI. (C,F) Representative fluorescent images (left) and quantitative graphs (right)
showing+aSMA (red) cells and+F4/80 cells (green). (*P,0.05, n = 5–7/group, 3 independent experiments; ns, p is not significant; Bar = 50 mm; Q-PCR
results were normalized to wild type control).
doi:10.1371/journal.pone.0068640.g004
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with this a known DAMP, HMGB1 was readily identified in the
preparation. Further studies beyond the scope of the current
studies should identify these DAMPs.
Because TLRs have been implicated as effectors in kidney
diseases [45,46] and TREM-1 has been previously linked to TLR
signaling, we investigated TLR-2 and TLR-4 as putative receptors
Figure 5. The TLR-2/TLR-4/MyD88 pathway is dispensable in macrophage activation in kidney fibrosis, but important in
mesenchyme cell activation. (A–C) Csf1R-icre; Myd88fl/fl mice or respective controls were subjected to U-IRI and kidney harvested for tissue
analysis 5 days later. Q-PCR (A) for different inflammatory transcripts, (B) pro-fibrotic transcripts, collagen1a1 (col1a1) and alpha smooth muscle actin
(Acta2), and the tubule injury marker, kidney injury molecule-1 (Kim-1) from whole kidney day 5 after U-IRI. (C) Representative fluorescent images
(left) and quantitative graphs (right) showing+aSMA (red) cells and+F4/80 cells (green). (D–E) Primary pericytes were isolated from Myd882/2 and
Tlr2–42/2 mice and stimulated in vitro for 8h with kidney DAMPs. (D) Graph showing Il-6 and Col1a1 transcript expression by Q-PCR. (E) Graph
showing IL-6 and MCP-1 concentration in supernatant by ELISA. (*P,0.05, n = 5–7/group, 3 independent experiments; ns, p is not significant;
Bar = 50 mm; Q-PCR results were normalized to wild type control).
doi:10.1371/journal.pone.0068640.g005
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for kidney DAMPs and macrophage activation. The studies
presented here show a significant role for TLR-2, TLR-4 and
MyD88 in vivo, particularly in the U-IRI model of chronic
inflammation, but indicate they are not important in macrophage
activation, even though macrophages during chronic kidney injury
contribute to disease progression and fibrogenesis [2] [3]. Both the
in vitro studies and in vivo studies implicate other signaling pathways
that are more important in macrophage activation in kidney
disease. Strikingly, we also identified C-type lectin (Clec) 4d and
Clec4e as kidney macrophage PRRs in the transcriptional
profiling experiments. Clec4e, also known as MINCLE, was
reported to be a critical PRR in macrophages responding to the
mitochrondrial spliceosomal protein SAP130, and signals through
FcRc [47]. We previously published that FcRc deficient mice
exhibit a significant reduction in injury and fibrosis in these models
of kidney injury. However the interacting receptors involved in this
activation were not determined [35]. Since these current studies
have ruled out a role for TREM-1 in macrophage activation in the
kidney future studies should determine whether the Clec receptors
play dominant roles via FcRc in kidney macrophage activation.
Although TLR signaling has been implicated in kidney diseases
in other studies [45], the role of these receptors in different cell
compartments in the kidney has been controversial and has been
thought to depend on the model of injury. Using a bone marrow
chimeric approach, it has been suggested that TLRs may play a
more important role in parenchymal cells rather than myeloid cells
during acute kidney injury [48,49]. Our findings would support
that. However our studies do not indicate that epithelial cell injury
is reduced when MyD88 or TLR-2 and TLR-4 are absent,
implicating other kidney cells. Until recently, the existence of the
mesenchymal cells in the kidney, known as pericytes and resident
fibroblasts, has been underappreciated but with new genetic tools
their roles in fibrogenesis and innate immunity as well as vascular
biology have recently become established [33,37,50]. Pericytes are
embedded in the peritubular capillaries of the kidney and, like
dendritic cells, form a barrier at the vascular interface [51–53].
Using a microarray approach, we have recently published that
during a progressive kidney disease, genes involved in the immune
response were highly upregulated in the pericyte to myofibroblast
transition in the kidney [37]. Although surprising, our studies
suggest that pericytes may form an important early immune
defense to injury by release of pro-inflammatory cytokines and
chemokines and that this response is highly dependent on TLR-2,
TLR-4 and MyD88. Further studies are required.
We conclude that TREM-1 and TLR-2, TLR-4 and MyD88
are dispensable in macrophage activation in sterile kidney injury
but that these pathways are important in activation of kidney
pericytes.
Supporting Information
Figure S1 Ly6C Macrophage subpopulations purified
from UUO kidney. (A) Representative plots of total kidney cells
from single cell preparation 5 days after UUO were selected for
viability and singularity by initial forward and side scatter gates.
(B) Ly6G+ and NK1.1+ cells were negative gated to exclude
neutrophils and NK cells. The different macrophage subpopula-
tion were sorted by gating populations of CD11b+ cells with three
levels of Ly6C expression: Ly6Chigh, Ly6Cint, and Ly6low.
(TIF)
Figure S2 Transcriptional analysis of activated macro-
phages in sterile kidney injury. Clustered profiles of 63
differentially expressed genes between Ly6C+ (Ly6Chigh and
Ly6Cint, n = 3/group) and Ly6Clow (n = 2) macrophages depicted
using a heatmap. Note the progressive decline in Trem1 expression
levels across Ly6Chigh, Ly6Cint, and Ly6Clow sub-populations.
Gene Ontology relational representation of highly enriched
functional modules corresponding to differentially expressed genes
between Ly6C+ and Ly6Clow macrophages. Prominent processes
include immune response, migration, chemotaxis, and cytokine
binding and activity.
(TIF)
Figure S3 Temperature sensitive kidney DAMPs acti-
vate macrophages ex vivo. (A) Q-PCR for Il-1b in BMDMw
primed with IFNc (0, 250 or 500 U/ml) for 8 hours, washed, and
further stimulated with kidney DAMPs for 12 hours. (B)
Coomassie blue stained SDS PAGE of crude preparation of
soluble extracellular factors from normal (control) and disease
kidney (kidney DAMPs). (C) Western blotting showing HMGB1
expression in soluble extracellular factors from control and kidney
DAMPs. (D) Q-PCRs from BMDMws treated with DAMPs for
16 h showing the effect of temperature changes on kidney DAMP
activity. (E) Q-PCR showing the effect of kidney DAMPs digestion
for 16 h with Trypsin (1:20 w/w ratio) or Pronase (1:50 w/w ratio)
prior application to BMDMw for 16 h. (*P,0.05, n= 5–7/group,
3 independent experiments; ns, p is not significant).
(TIF)
Figure S4 TREM-1 pathway is important for BMDMw
activation by LPS in vitro, but dispensable for activation
by kidney DAMPs. (A) Schema of TREM1-Fc fusion protein
and Western blot of purified TREM1-Fc, detected by anti-
TREM-1 antibodies. (B–C) Q-PCR for Il-1b in BMDMws
stimulated with LPS and treated with (B) TREM1-Fc or (C)
anti-TREM-1 antibodies. (D) Q-PCR for Il-1b in BMDMw pre-
incubated with kidney DAMPs for 8 h to induce TREM-1
expression, followed by kidney DAMPs in the presence of anti-
TREM-1 antibodies or TREM1-Fc for 16 h further. (E) Q-PCR
showing BMDMw response to DAMPs for 16 h that were pre-
adsorbed by hIgG or TREM1-Fc coated protein-A beads. (F–G)
Colorimetric assay reporting Lacz activity in BWZ-Lacz reporter
cells expressing TREM1-DAP12 chimera protein stimulated with
kidney DAMPs for 16 h in wells (F) pre-coated with kidney
DAMPs or (G) in suspension (anti-TREM-1 antibodies are positive
control). (n = 3–5/group, 3 independent experiments; *P,0.05).
(TIF)
Figure S5 Treatment with soluble TREM1-Fc does not
prevent macrophage activation, injury and fibrosis in
UUO model of sterile kidney injury. Mice were subjected to
unilateral ureter obstruction (UUO) and treated daily with 40 mg/
mouse of TREM1-Fc or hIgG, as control. (A) Q-PCR for different
inflammatory transcripts (left) or pro-fibrotic transcripts, Col-
lagen1a1 (Col1a1) and alpha smooth muscle actin (Acta2), from
whole kidney day 5 after UUO. (B) Representative images (left)
and quantitative graphs (right) showing+F4/80 cells (green),+-
aSMA (red) or collagen deposition (Sirius Red staining) day 5 after
UUO. (*P,0.05, n= 5–7/group, 3 independent experiments; Bar
marker = 50 mm; Q-PCR data were normalized to sham+higG
control).
(TIF)
Figure S6 The TLR2/4/MyD88 pathway is dispensable
in the UUO model of sterile kidney injury. (A,C,E) Q-
PCR for different inflammatory molecules, pro-fibrotic transcripts,
collagen1a1 (col1a1) and alpha smooth muscle actin (Acta2), and
the tubule injury marker, kidney injury molecule-1 (Kim-1) from
whole kidney day 5 after UUO in (A) Myd882/2, (C) Tlr2–42/2,
and mice lacking MyD88 only in myeloid cells lineage, (E) Csf1R-
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icre; MyD88fl/fl. (B,D,F) Graphs showing quantification of
fluorescent images for+aSMA cells and+F4/80 cells. (*P,0.05,
n = 5–7/group; Q-PCR data were normalized to wild type sham).
(TIF)
Figure S7 Validation of MyD88 conditional ablation in
myeloid cells expressing Csf1R. Csf1R-iCre mice were
crossed with Myd88fl/fl to generate Csf1R-icre; Myd88fl/fl mice,
which selectively ablates MyD88 expression in myeloid cells
expressing Csf1R. (A) Western blot showing basal or LPS-induced
MyD88 expression of BMDMw isolated from Csf1R-icre; Myd88+/+
or Csf1R-icre; MyD88fl/fl. (B) Q-PCR for Il-1b expression of
BMDMw from Csf1R-icre; Myd88+/+, Csf1R-icre; MyD88fl/fl,
Myd88+/+ and Myd882/2 mice stimulated with LPS for 16h.
(*P,0.05, n= 3–5/group; Q-PCR data were normalized to wild
type control).
(TIF)
Table S1 Quantitative PCR from kidney tissue day 5
after U-IRI injury.
(DOCX)
Methods S1.
(DOCX)
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